Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
GIST
Do you always send for SDHB by IHC for workup of GIST? or is NGS/FISH that includes SDHB sufficient?
Related Questions
Do you modify the dose of Naliri in Nalirifox for patient that are heterozygous for UGT1A1 mutations?
Which patients, if any, do you revert back to ultrasound screening for HCC after prior diagnosis/definitive treatment of HCC?
What initial systemic therapy would you offer a patient with metastatic colon cancer with BRAF V600E mutation, MSS, who is not an oxaliplatin candidate?
Will you offer durva-FLOT perioperatively for adenocarcinoma of the esophagus with PDL1<1?
With recent PFS data from LEAP-012 and Emerald-1, do you routinely offer for patients with intermediate BCLC stage HCC undergoing TACE or TARE systemic therapy (pembro/lenva or durve/bev)?
Would you consider the use of avapritinib in advanced GIST after failure of imatinib, sunitinib and ripretinib in exon 11 and 17 kit mutated GIST?
What treatment sequence do you follow for patients with rectal cancer who are candidates for both PROSPECT and TNT/Watch and wait?
How should immunotherapy be incorporated into the treatment strategy for patients with resectable stage III microsatellite instability–high (MSI-H) or mismatch-repair-deficient (dMMR) extrahepatic cholangiocarcinoma?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
How would you treat an early-stage dMMR rectal squamous cell carcinoma in an otherwise healthy elderly patient?
